R & D

Zykos has future plan to invest in R & D.

rd

The 2026 Preferred R&D Operating Model

  • In-House (The Brain): Keep IP generation, AI/ML drug design, and clinical strategy in-house.
  • Outsourced (The Muscle): Use CDMOs and Cloud Labs for synthesis and animal studies to avoid high upfront machinery costs.
  • AI Integration: 41% of R&D leaders in 2026 are now automating entire discovery workflows with AI Agents that can predict molecule toxicity before a single test tube is touched.
picture5